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Background & aims: Innate immunity is the first line of defense against invasive microbial infection, and AIM2
plays an important role in this process by sensing double-stranded DNA viruses. However, the role of AIM2 in
regulating the immune response to viruses in vivo, especially in sensing hepatitis B virus (HBV), has not been examined.
We hypothesized that the expression of AIM2 increases corresponding to HBV-mediated inflammation in patients with
hepatitis B virus associated glomerulonephritis (HBV-GN), a condition which activates inflammatory mechanisms and
causes renal damage. To test this hypothesis, we analyzed the expression of AIM2 in HBV-GN patients in relation to the
inflammatory response to HBV infection.
Methods: A total of 79 patients diagnosed with chronic nephritis (CN) were enrolled in this study, including 54 HBV-GN
patients as the experimental group and 24 chronic glomerulonephritis (CGN) patients as the negative control group. Six
patients diagnosed with chronic hepatitis B (CHB) were also enrolled as positive controls. Each CN patient received renal
biopsy, and immunohistochemistry was used to detect the expression of AIM2 and inflammatory factors caspase-1 and
IL-1β in the biopsy specimens. CHB patients received liver puncture biopsy, and immunohistochemistry was
used to detect the expression of AIM2 in these specimens. Expression of AIM 2 among different groups and in
relation to inflammatory factors caspase-1 and IL-1β was analyzed.
Results: The expression of AIM2 in HBV-GN patients (81.4%) was significantly higher than in CGN patients
(4.0%). Among the HBV-GN patients, expression of AIM2 was significantly higher in the high HBV replication
group than in the low HBV replication group. AIM2 expression was not correlated with age, gender, HBeAg status in
serum, HBV-antigen type deposited in renal tissue or pathological type of HBV-GN. However, AIM2 levels were positively
correlated with the expression of caspase-1 and IL-1β in HBV-GN patients. The data suggest that AIM2 expression
is directly correlated with HBV infection-associated inflammation.
Conclusion: The elevation of AIM2 during HBV infection or replication may contribute to its associated
inflammatory damage, thus providing a putative therapeutic target and a new avenue for researching the
pathogenesis of HBV-GN.
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Hepatitis B virus (HBV) infection has been shown to in-
duce several extra-hepatic lesions [1], One of the most
common manifestations is hepatitis B virus associated
glomerulonephritis (HBV-GN) [2]. Since the association
between HBV infection and glomerular diseases was first
reported by Combes et al. in 1971 [3], more HBV-GN
cases have been described all over the world. The exist-
ence of HBV DNA in the renal tissue of some nephritic
patients led to the classification of HBV-GN, proposing
a role for HBV in its pathogenesis [4]. However, the spe-
cific pathogenesis of HBV-GN is still unclear. The widely
accepted view is that persistent viral infections could
lead to immune complex-mediated nephritis [5].
Absent in melanoma 2 (AIM2) is a member of the
HIN-200 protein family [6] and can bind to double-
stranded DNA (ds-DNA) and to the adaptor molecule
ASC (apoptosis-associated speck-like protein), which
contains a caspase activation and recruitment domain.
This complex then activates caspase-1 and leads to the
formation of mature IL-1β. An important intracellular
inflammatory cytokine, maturation and secretion of IL-1β
causes subsequent tissue damage [7]. Although AIM2 is
known to be involved in the host defense against micro-
bial invasion, its role in regulating the immune response
to viruses, especial to HBV, has not been well understood.
HBV is a ds-DNA virus, and HBV particles have been
shown to be detectable in the kidneys of HBV-GN pa-
tients [4]. Cytoplasmic HBV-DNA in the kidneys has a
chance to be recognized by AIM2. The potential bin-
ding of AIM2 to HBV-DNA may lead to the activation
of caspase-1 and subsequent maturation and secretion
of IL-1β. This cascade of events leads to the development
of the inflammasome, which may then be responsible for
the renal damage seen in HBV-GN patients.
In this study, we compared the expression of AIM2 in
HBV-GN and chronic glomerulonephritis (CGN) and
further explored the relationship between the expression
of AIM2, caspase-1 and IL-1β. Our results showed that
AIM2 expression is high in HBV-GN and correlated
with both serum HBV-DNA titer and renal inflamma-
tion associated with HBV-GN, thus AIM2 may play an




Our retrospective study was approved by the ethics
committee of Jinan Infectious Disease Hospital. A total
of 79 patients diagnosed with chronic nephritis, identi-
fied between 2008 and 2011 at Jinan Infectious Disease
Hospital and QiLu Hospital of Shandong University
Shandong, China, were included in the study. The ex-
perimental group consisted of 54 HBV-GN patients, thenegative control group consisted of 25 CGN patients,
and six chronic hepatitis B (CHB) patients served as the
positive control group. The six CHB patients were serum
HBeAg-positive and had HBV-DNA titers of more than
1 × 105 copies/ml. Subjects received either kidney (CGN)
or liver (CHB) puncture biopsy under ultrasound guid-
ance to attain nephridial tissue or hepatic tissue, respect-
ively, for diagnosis and subsequent research. Participation
was dependent upon fulfillment of the following criteria:
(1) patients must not have used an immune agent or anti-
viral agent in the past three months; (2) patients must not
have HAV, HCV, HDV, HEV or HIV co-infection; (3)
patients must not have a history or current evidence of
secondary glomerulonephritis; and (4) consent for par-
ticipation must have been obtained from those who
participated.
Diagnosis of HBV-GN, CGN and CHB
The diagnostic criteria used for CGN and HBV-GN were
in accordance with the 2002 Kidney Disease Outcome
Quality Initiative (K/DOQI), edited by the National Kid-
ney Foundation (NKF) [8]. The diagnosis of HBV-GN
was confirmed by pathology. Frozen slices from biopsies
of the 54 HBV-GN patients were kept in a low-temperature
freezer. Monoclonal goat-anti-human HBsAg and HBcAg
antibodies were purchased from Dako (Denmark), and im-
munohistochemical staining for HBsAg and HBcAg in renal
biopsies was used to confirm the diagnosis (Figure 1A). For
HBV-GN patients with undetectable HBsAg or HBcAg in
nephridial tissue, HBV was detected using the JCM-6000
scanning electron microscope from Jeol, Ltd. (Japan).
The diagnostic criteria used for CHB were in accor-
dance with the Asian-Pacific Consensus Statement on
the Management of Chronic Hepatitis B [9].
The pathological classification of HBV-GN
The pathological classification of and diagnostic criteria
used for HBV-GN were in accordance with 1990 WHO
classification criteria [10]. Sections from all biopsy speci-
mens were stained routinely with hematoxylin and eosin
(H&E), periodic acid-sliver methenamine (PASM), Masson’s
trichrome and antibodies against IgA, IgG, IgM, C3
and C1q complement component. Fluorescently-labeled
IgA, IgG, IgM, C3 and C1q rabbit-anti-human antibodies
were purchased from Dako.
Immunohistochemistry and scoring
Nephridial and hepatic tissue specimens were first fixed
in 10% formalin, then the tissue was cut, dehydrated,
dipped in wax, embedded and sectioned. These sections
were then placed on slides, baked, placed into xylene,
cleared of the wax, rehydrated using graded ethanol and
immersed in 0.3% hydrogen peroxide for five minutes
to reduce non-specific background staining caused by
Figure 1 Immunohistochemical staining. A: HBsAg positive staining in glomerular endothelial cells and mesangial cells in HBV-GN (Magnification
of 400x). B: AIM2 positive staining in hepatic cytoplasm in CHB (Magnification of 400x). C: AIM2 positive staining in glomerular endothelial
cells and mesangial cells in HBV-GN (Magnification of 400x). D: Caspase-1 positive staining in glomerular endothelial cells and mesangial cells
in HBV-GN (Magnification of 400x). E: IL-1β positive staining in glomerular endothelial cells and mesangial cells in HBV-GN (Magnification of 400x).
F: AIM2, Caspase-1 and IL-1β negative staining in glomerular endothelial cells and mesangial cells in CGN (Magnification of 400x).
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with PBS buffer three times for five minutes each,
placed in citrate buffer solution at a pH of 6.0 and then
into a high temperature pressure pot to recover the tis-
sue antigen. After being heated, the slides were cooled
and restored at room temperature, washed three more
times in PBS buffer and incubated with AIM2 (ab93015,
rabbit anti-human polyclonal antibody; Abcam, USA),
caspase-1 (sc-56063,mouse anti-human polyclonal anti-
body; Santa Cruz Biotechnology Inc., USA) and IL-1β
antibodies (ab2105, rabbit anti-human polyclonal anti-
body; Abcam), respectively. The slides were then placed in
a 4°C refrigerator overnight. The next day, the slides were
washed with PBS buffer three times, each time lasting lon-
ger than five minutes, then incubated with the secondary
antibody PV-9000 (universal antibody) at 37°C for 10 mi-
nutes, washed with PBS buffer, and DAB staining was ap-
plied. The stain was terminated using running water, then
the slides were washed with hydrochloric acid alcohol for
differentiation. Lastly, the slides were washed with distilled
water, cleared with xylene and mounted.
Appearance of a tan stain in the cytoplasm signaled
positive expression of the protein. After staining, scores
were assigned based on stain intensity and percentage of
positive cells as follows: For stain intensity, a score of 0was given for no brown staining (i.e., no cells stained), 1
for light brown, 2 for brown and 3 for dark brown; for
percentage of positive cells, a score of 0 was given for
fewer than 5% positive cells, 1 for 5% to 30%, 2 for 30%
to 60% and 3 for greater than 60%. Scores for stain in-
tensity and percent positive were then added together,
and a negative sign (−) was assigned for scores totaling
0, mildly positive (+) for scores between 1 and 3, mode-
rately positive (++) for scores between 4 and 6 and
strongly positive (+++) for scores greater than 7.
Statistical analysis
The SPSS program (version 17.0) was used for analysis.
Measurement data was described as mean ± standard de-
viation. Background factors were compared using the
Student’s t-test (numerical data) or the Chi-square test
(categorical data). Spearman’s two-tailed test was used for
correlation analysis, and differences were regarded as sig-
nificant if the p value was less than 0.05 on either side.
Results
Expression of AIM2 was significantly high and correlated
with HBV load in HBV-GN
To study the role of AIM2 in HBV-GN, we compared
the expression of AIM2 in 54 HBV-GN and 25 CGN
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CHB patient liver specimens was confirmed by immuno-
histochemistry. The results showed that AIM2 expres-
sion was exclusive to the hepatic cellular cytoplasm in
liver tissue (Figure 1B) and the cellar cytoplasm of glom-
erular endothelial cells and mesangial cells in nephridial
tissue. Statistical analysis revealed that the positive ex-
pression rate of AIM2 in HBV-GN patients was sig-
nificantly higher than in CGN patients (81.4% vs.
4.0%, p < 0.01) (Table 1). Notably, AIM2 expression was
not affected by age (p = 0.06) or gender (p = 0.527).
To further clarify the factors affecting the expression
of AIM2 in HBV-GN patients, we considered the poten-
tial influence of age, gender, HBeAg status and HBV titer
in serum. As summarized in Table 2, the results showed
that AIM2 expression was not affected by age (p = 0.937)
or gender (p = 0.627). Using ELISA, serum HBeAg de-
tected in 47 of the 54 HBV-GN patients showed that
AIM2 expression was also not affected by HBeAg status
(p = 0.614). However, in assessing HBV titers, real-time
PCR detected serum HBV-DNA in 24 of 54 tested HBV-
GN patients, and we found that the expression of AIM2
was significantly higher in patients with high viral load
(HBV-DNA ≥ 1 × 105copies/ml) than in patients with
low viral load (HBV-DNA < 1 × 105 copies/ml) (p < 0.05).
These results suggested that the expression of AIM2
may be dependent on HBV load in HBV-GN.Expression of AIM2 is not correlated with HBV-antigen
type deposited in nephridial tissue or with pathological
type of HBV-GN
To test whether the expression of AIM2 may be influ-
enced by various HBV-antigen types deposited in neph-
ridial tissue, we compared the expression of AIM2
among groups with various HBV antigens deposited in
nephridial tissue. As summarized in Table 3, the results
showed no difference in the expression of AIM2 among
various HBV-antigen groups (p = 0.511).
We also analyzed the expression of AIM2 among vari-
ous pathological types of HBV-GN. As summarized in
Table 4, the results showed no difference in the expres-
sion of AIM2 among various pathological types of HBV-
GN (p = 0.940).Table 1 The expression of AIM2 is high in HBVGN
Group Tissue n Age Gender M
HBV-GN K 54 36.1 ± 12.7 35(64.8
CGN K 25 38.2 ± 15.5* 18(72.0)
CHB L 6 33.0 ± 8.7 6(100
HBV-GN, Hepatitis B viral associated glomerulonephritis; CGN, Chronic glomerulone
(t = −1.909, p = 0.06); **compared with HBV-GN, (x2 = 0.400, p = 0.527); ***compaExpression of AIM2 was correlated with inflammation in
HBV-GN
IL-1β is widely accepted to be an important pro-
inflammatory factor contributing to the development
of chronic renal inflammation. To reveal what role
AIM2 plays in HBV-GN patient renal damage, we ana-
lyzed the correlation between the expression of AIM2,
caspase-1 and IL-1β. Statistical analysis revealed that
the expression of AIM2 was positively correlated with
that of caspase-1 (rs = 0.444, p < 0.01) and IL-1β (rs =
0.379, p < 0.01), and expression of caspase-1 was posi-
tively correlated with that of IL-1β (rs = 0.515, p < 0.01)
(Table 5). Figure 1C, D and E illustrate the positive ex-
pression of AIM2, caspase-1 and IL-1β, respectively, in
these patients, and Figure 1F shows the negative ex-
pression of AIM2 in CGN. These results suggested that
the expression of AIM2 was specifically correlated with
inflammation in HBV-GN and that elevation of AIM2
corresponding to HBV infection or replication may
contribute to the inflammatory damage associated with
the development of HBV-GN.Discussion
AIM2 was first reported to act as a putative tumor sup-
pressor in malignant melanoma [11]. Recent research
demonstrated that AIM2 plays an important role in the
innate immune response through sensing potentially
dangerous cytoplasmic ds-DNA and inducing the forma-
tion of the ASC inflammasome, which then induces the
activation of caspase-1 and release of mature IL-1β [7].
Maturation and secretion of IL-1β, an important intra-
cellular cytokine belonging to the IL-1 superfamily [12],
ultimately leads to tissue damage [13]. As a non-specific
receptor for cytoplasmic DNA, AIM2 can be activated
by and bind to plasmid DNA, DNA from the bacterium
Listeria monocytogenes and even synthetic ds-DNA [14].
Previous research detected AIM2 in the small intestine,
spleen, peripheral white blood cells and testis [15]. Our
study describes the inducible expression of AIM2 in liver
and kidney tissue and the exclusive expression of AIM2
in the hepatic cytoplasm and glomerular endothelial cell
and mesangial cell cytoplasm in the kidney. These re-
sults further suggest that AIM2 may play an important(%) AIM2 Positive
rate(%)- + ++ +++
) 10 26 18 0 81.4
** 24 1 0 0 4.0***
) 0 0 6 0 -
phritis; CHB, Chronic hepatitis B; K, kidney, L, liver; *compared with HBV-GN,
red with HBV-GN, (x2 = 38.746, p < 0.01).
Table 4 Expression of AIM2 was negatively correlated
with various pathological types of HBV-GN
AIM2
Pathological type n(%) - + ++ X2 p
MsPGN 15(27.8) 3 8 4
MPGN 9(16.7) 1 5 3
MN 27(50.0) 6 11 10
MCG 1(1.8) 0 1 0
FSS 2(3.7) 0 1 1
Total 54 10 26 18 2.905 0.940
MsPGN, Mesangioproliferative glomerulonephritis; MPGN,
Membranoproliferative glomerulonephritis; MN, Membranous nephropathy;
MCG, Minimal change glomerulopathy; FSS, Focal segmental sclerosis.
Table 2 Expression of AIM2 was correlated with serum
HBV load in HBV-GN
AIM2
n(%) - + ++ X2 p
Gender, M 35(64.8%) 0.131 0.937
Age (y) 2.598 0.627
≤20 5(9.3%) 2(20.0%) 2(7.7%) 1(5.6%)
21-40 29(53.7%) 4(40.0%) 16(61.5%) 9(50.0%)
≥41 20(37.0%) 4(40.0%) 8(30.8%) 8(44.4%)
e-Ag (+) 33(70.2%) 6(60.0%) 16(69.6%) 11(78.6%) 0.975 0.614
HBV-DNA
≥105 cp/ml 16(66.7%) 5(83.3%) 10(76.9%) 1(20.0%) 6.097 0.047
M, male; e-Ag, HBeAg; cp/ml, copies/ml.
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and may provide a new avenue for researching the
pathogenesis of CHB. We found that the positive expres-
sion rate of AIM2 in the HBV-GN group was signifi-
cantly higher than that of the CGN group. As neither
age nor gender were statistically different between the
two groups, this suggests that there is indeed a relation-
ship between chronic HBV infection and AIM2 eleva-
tion. We also considered another potential influence
factor, HBeAg status in serum, which may have contrib-
uted to the mutation of the HBV-DNA-P-BCP (basal
core promoter) or pre-C region, influencing AIM2 acti-
vation and binding to HBV-DNA. Our results showed
that the expression of AIM2 was not significantly differ-
ent between the HBeAg positive and negative groups,
demonstrating that AIM2 activation and binding to HBV-
DNA is not influenced by serum HBeAg status. Moreover,
our results indicated that the positive expression rate of
AIM2 in the high replication group (HBV-DNA ≥ 1 × 105
copies/ml) was significantly higher than that of the low
replication group (HBV-DNA < 1 × 105 copies/ml), sug-
gesting that high HBV load led to the increase in AIM2
expression. A recent study focusing on the relationship
between AIM2 expression and acute and chronic hepatitis
B infection showed that AIM2 mRNA expression wasTable 3 Expression of AIM2 was negatively correlated
with various HBV antigen deposited in kidney tissue in
HBV-GN
AIM2
n(%) - + ++ X2 p
s-Ag+,c-Ag+ 22(40.7) 5 10 7
s-Ag+,c-Ag- 24(44.4) 4 12 8
s-Ag-,c-Ag+ 6(11.1) 1 4 1
s-Ag-,c-Ag- 2(3.7) 0 0 2
Total 54 10 26 18 5.259 0.511
s-Ag = HBsAg; c-Ag = HBcAg.negatively correlated with serum HBV load [16]. This
study included acute hepatitis B (AHB) and chronic hepa-
titis B (CHB) patients. The pathogenesis of AHB and CHB
is widely accepted to be high HBV load assault and im-
mune injury, respectively, though the pathogenesis of each
in the study was unclear. For both AHB and CHB, only in-
flammation (i.e., immune injury) was noted. The role of
AIM2 in regulating the immune response to viral infection
can hereby be emphasized. A higher HBV load provides a
greater opportunity to bind AIM2 and lead, subsequently,
to activation of the inflammation signal pathway. How-
ever, some of the CHB patients in the characteristic stages
of immune tolerance, immune clearance, inactive-carrier
and reactivation in this study exhibited no inflammation.
In our present study, all HBV-GN patients exhibited in-
flammation. Moreover, the pathogenesis of CHB and
HBV-GN is different. As for the role of HBV in HBV-GN
pathogenesis, it needs to be explored further. Previous re-
search reported that high HBV-DNA load was correlated
with HBV-GN-related morbidity [4]; however, the specific
pathogenesis for this has been unclear until now. Our re-
sults have demonstrated that this morbidity may be due to
the high HBV-DNA load of these patients having a greater
chance to activate AIM2, resulting in the release of in-
flammatory cytokines and subsequent renal damage.
Several HBV antigens, including HBsAg and HBcAg,
have been found deposited in the glomerulus and thought
to contribute to the pathogenesis of HBV-GN [17]. OurTable 5 Expression of AIM2 was positively correlated with
caspase-1 and IL-1β in HBV-GN
AIM2 Caspase-1 IL-1β
- + ++ +++ - + ++ +++
- 7 2 1 0 11 19 4 0
+ 4 19 3 0 4 16 7 0
++ 2 9 6 1 3 6 8 1
AIM2 was positively correlated with caspase-1 (rs = 0.444, p < 0.01); AIM2 was
positively correlated with IL-1β (rs = 0.379, p < 0.01); caspase-1 was positively
correlated with IL-1β (rs = 0.515, p < 0.01).
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with the type of HBV-antigen deposited in nephridial tis-
sue, suggesting also that AIM2 binding to HBV-DNA was
not dependent on HBV-antigen type deposited. Previous
research demonstrated that different pathological types of
HBV-GN have different clinical outcomes [18], so we fur-
ther analyzed the expression of AIM2 among various
pathological types within the HBV-GN group. The results
demonstrated that the expression of AIM2 was not af-
fected by these various pathological types of HBV-GN,
suggesting that inflammation due to AIM2 activation
commonly exists irrespective of pathological type.
IL-1β is an important intracellular cytokine which binds
to receptors and activates the downstream NF-ĸB signaling
pathway, releasing inflammatory factors that cause tissue
damage. Our results showed that the expression of AIM2
was positively correlated with the expression of caspase-1
and IL-1β in HBV-GN. HBV particles were detectable using
scanning electron microscopy in nephridial tissue from
HBV-GN patients [4]. During the innate immune response
to invading HBV, activated AIM2 may bind to ASC, indu-
cing activation of caspase-1 and releasing IL-1β [7]. Similar
results were obtained in the recent Wu study focusing on
the relationship between AIM2 expression and acute and
chronic hepatitis B infection [16], suggesting that AIM2
plays an important role in both HBV-GN and hepatitis B
infection. As long as HBV is present, AIM2 may be acti-
vated and lead to subsequent inflammatory injury. Our
study further confirms this mode of signal transduction.
Within the experimental group, the expression level of
AIM2 was positively correlated with the level of caspase-1,
and the level of caspase-1 was positively correlated with the
level of IL-1β, suggesting that this inflammation signal
transfer pathway was related to AIM2 levels in HBV-GN
and, subsequently, that AIM2 may play an important role
in the pathogenesis of HBV-GN.
In summary, we found the expression of AIM2 to be
significantly increased in HBV-GN patients. AIM2 levels
were highly correlated with HBV load and inflammation
in HBV-GN. Collectively, these results suggest that the
elevation of AIM2 during HBV infection or replication
may contribute to renal damage due to inflammation.
Our findings may help provide a new therapeutic target
for HBV-GN and a new avenue for researching its
pathogenesis.
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